A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19

• Main Authors: Keisuke Nakamura (Author), Katsukuni Fujimoto (Author), Chihiro Hasegawa (Author), Ikuo Aoki (Author), Hiroyuki Yoshitsugu (Author), Hiroyuki Ugai (Author), Naoyoshi Yatsuzuka (Author), Yoshiyuki Tanaka (Author), Kenichi Furihata (Author), Brian M. Maas (Author), Prachi K. Wickremasingha (Author), Kelly E. Duncan (Author), Marian Iwamoto (Author), Selwyn A. Stoch (Author), Naoto Uemura (Author)
• Format: Book
• Published: Wiley, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We conducted a phase I safety and pharmacokinetic study of molnupiravir...